Login
Azenta, Inc. logo

Azenta, Inc.

azenta.com

What Do They Do?

Provides sample-management and genomic services to pharmaceutical and biotechnology companies, research hospitals, and academic and government institutions. Sells automated sample-storage systems and laboratory products to those customers.

How Do They Make Money?

Azenta bills for sample-storage, genomic and support services, as well as products, under contracts with generally fixed amounts; payment generally comes within a year after the service or product is provided.

revenue
SegmentShareRevenue
Product
Sold outright

29%
FY2022: 33%
Service
71%
FY2022: 67%

Who Are Their Customers?

Pharmaceutical and biotechnology companies, research hospitals, academic and government institutions, and biotech start-ups buy from Azenta. Most sales, including storage systems, storage services and genomic services, are direct; distributors help sell consumables and instruments and support sales in emerging markets.

Do Revenues Turn Into Profits?

Not on paper. It lost $55.8M in FY2025, but brought in more cash than it spent: $38.3M of free cash flow.

Operating income, FY2025
−5% of revenue
▲ +48% (Loss) vs FY2024 (−$51.3M, −9%)
Net income, FY2025
−9% of revenue
▲ +66% (Loss) vs FY2024 (−$164.9M, −29%)
Free cash flow, FY2025
6% of revenue
▲ +210% vs FY2024 ($12.4M, 2%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Jun 30, 2026
Revenue
▲ +12%
vs $143.9M in Q3 FY2025
Net income
▲ Turned profitable
vs −$48M in Q3 FY2025
Services share of revenue vs 72.6% in Q3 FY2025
  • Oct 28, 2026 Azenta acquired SynPlexity and licensed Elegen gene-synthesis technology The company plans to integrate SynPlexity technology into GENEWIZ and use Elegen technology to expand gene-synthesis capabilities.
  • Aug 22, 2026 John Marotta resigned as CEO; Martin Madaus became interim CEO
  • Jul 1, 2026 Azenta completed the sale of B Medical Systems

Growing. Revenue grew 16% in 4 years, from $513.7M in FY2021 to $593.8M in FY2025, about 4% a year.

B Medical's place in the portfolio The older report described B Medical as an addition to the cold-chain portfolio; the latest treats it as held for sale and excludes it from continuing operations.

Support through commercialization The latest report says Azenta supports customers through commercialization, extending beyond the older report's stated span from research to clinical development.

Revenue over time
Product Service
$1B$500M$0

Who Do They Compete With?

Competes with Hamilton, Liconic, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, BGI Genomics, Eurofins, Scientific, GenScript Biotech, Integrated DNA Technologies, Novogene, and Twist Bioscience

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support